Petauri Enhances Market Access Abilities with New Senior Leaders

Petauri Expands Leadership to Enhance Market Access Insights

Petauri, a specialized pharmaceutical services platform, is making significant strides in the life sciences consulting sector through the recent addition of two key senior industry leaders. This move is expected to bolster their commercialization insights and access strategy divisions, enhancing the overall capability of Petauri Advisors.

Enhancing Consulting Expertise

In a statement, Dan Vanderpoel, President of Petauri Advisors, expressed the company's commitment to delivering real-world expertise. He highlighted that both newly appointed leaders possess a wealth of experience on the client side of decision-making processes—specifically regarding formulary decisions and access strategies. Vanderpoel remarked, “These additions represent exactly the type of real-world expertise our clients are seeking.”

With the complexities surrounding healthcare access on the rise, it is imperative that organizations like Petauri adapt and offer tailored solutions to navigate these challenges.

New Leadership Profiles

Chris Stewart

Chris Stewart joins Petauri with over two decades' worth of experience in market access. His most recent role was as Vice President of Manufacturer Trade Relations and Operations at Humana. While there, he successfully led value-based contracting strategies across multiple business lines. Stewart’s extensive background in federal and state drug policies and regulatory risk management further enhances Petauri's capabilities in providing insightful market access strategies.

Vibha Goel

Vibha Goel comes to Petauri with rich experience in pharmaceutical benefits management (PBM) and clinical leadership. She has held various senior clinical account executive positions, with her last role at Evernorth/Express Scripts. Goel has collaborated with cross-functional teams to support formulary decisions, new product launches, and rebate strategies. Her hands-on experience in clinical operations, specifically in pediatric and oncology care, will enrich Petauri's approach to market access strategies.

A Strategic Move

Vanderpoel added, “As access dynamics become more complex, theoretical solutions are no longer enough.” It is clear from this change that Petauri is prioritizing experience-driven solutions, allowing them to provide actionable advice that reflects the challenges faced by their clients.

Petauri aims to create a credible framework for engaging payers and healthcare systems, supported by the rich perspectives these new leaders bring to the table. This strategic addition signifies Petauri's ongoing commitment to meeting the diverse needs of life sciences organizations.

About Petauri

Founded in 2023 by CEO Dan Renick in partnership with Oak Hill Capital, Petauri is focused on establishing its expertise across various facets of pharmaceutical services. The company is making waves in the industry by launching, acquiring, and merging top-tier companies that possess specialized skills in global market access, medical affairs, and patient services.

Since its inception, Petauri has expanded its portfolio by incorporating firms like The Kinetix Group and the agencies of FORCE Communications, enhancing its offerings under various business units, including Petauri Advance and Petauri Evidence.

With a pledged investment of over $250 million from Oak Hill's latest fund, Petauri is positioned to improve patient outcomes by ensuring that the value of medical advances can be systematically established within the complex healthcare system.

For more updates and information, visit Petauri’s official website.